Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker LXRX
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | Michael Exton Chief Executive Officer, Director | LXRX Lexicon Pharmaceuticals, Inc. | Buy | 30,064 | $1.66 | $50.0K Buy | Form 4 ↗ |
| Feb 25, 2026 | Raymond Debbane Director | LXRX Lexicon Pharmaceuticals, Inc. | Buy | 2,000 | $1.49 | $2,980 Buy | Form 4 ↗ |
| Feb 23, 2026 | Raymond Debbane Director | LXRX Lexicon Pharmaceuticals, Inc. | Buy | 100,000 | $1.47 | $147.0K Buy | Form 4 ↗ |
| Feb 20, 2026 | Raymond Debbane Director | LXRX Lexicon Pharmaceuticals, Inc. | Buy | 100,000 | $1.48 | $148.0K Buy | Form 4 ↗ |
| Feb 19, 2026 | Raymond Debbane Director | LXRX Lexicon Pharmaceuticals, Inc. | Buy | 50,000 | $1.44 | $72.0K Buy | Form 4 ↗ |
| Feb 18, 2026 | Raymond Debbane Director | LXRX Lexicon Pharmaceuticals, Inc. | Buy | 133,688 | $1.32 | $176.5K Buy | Form 4 ↗ |
| Feb 17, 2026 | Raymond Debbane Director | LXRX Lexicon Pharmaceuticals, Inc. | Buy | 76,857 | $1.31 | $100.7K Buy | Form 4 ↗ |
| Feb 13, 2026 | Raymond Debbane Director | LXRX Lexicon Pharmaceuticals, Inc. | Buy | 57,952 | $1.31 | $75.9K Buy | Form 4 ↗ |
| Feb 2, 2026 | Artal Group S.A. Director, 10% owner | LXRX Lexicon Pharmaceuticals, Inc. | Buy | 1.54M | $1.30 | $2.0M Buy | Form 4 ↗ |
9 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:31 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances